tiprankstipranks
Inmune Bio (INMB)
NASDAQ:INMB
US Market

Inmune Bio (INMB) Drug Pipeline

876 Followers
Drug Name
Condition
Stage
Status
Study Name
Trial Start Date
Article
Inkmune
Cancer, Metastatic Castration-Resistant Prostate Cancer, Mcrpc
Phase I/II
Completed
Study of INKmune in Patients With mCRPC (CaRe Prostate)
Aug 07, 2023
Xpro1595
Mental Disorders, Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders
Phase II
Terminated
An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease
Aug 18, 2022
Xpro1595
Neurocognitive Disorders, Mental Disorders, Tauopathies, Neurodegenerative Diseases, Central Nervous System Diseases, Nervous System Diseases, Dementia, Brain Diseases, Mild Cognitive Impairment, Alzheimer Disease
Phase II
Completed
A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation
Mar 07, 2022

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
    What is a clinical trial?
    A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
      What drugs does Inmune Bio (INMB) have in its pipeline
      INMB is currently developing the following drugs: Inkmune, Xpro1595, Xpro1595. These drug candidates are in various stages of clinical development as the company works toward FDA approval.